✦ LIBER ✦

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features

✍ Scribed by Jae-Lyun Lee; Inkeun Park; Kwonoh Park; Seongjoon Park; Yongcheol Ahn; Jin-Hee Ahn; Tae-Won Kim; Shin Ahn; Cheryn Song; Jun Hyuk Hong; Choung-Soo Kim; Hanjong Ahn

Book ID: 113043127
Publisher: Springer-Verlag
Year: 2012
Tongue: English
Weight: 317 KB
Volume: 138
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-012-1148-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An international expanded-access program

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

✍ Viktor Grünwald; Pierre I. Karakiewicz; Sevil E. Bavbek; Kurt Miller; Jean-Pasca 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 257 KB

High Frequency of Intracerebral Hemorrha

High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor

✍ Damien Pouessel; Stéphane Culine 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 130 KB

Effects of combined valproic acid and th

Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro

✍ Eva Juengel; Johanna Engler; Ausra Mickuckyte; Jon Jones; Lukasz Hudak; Dietger 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 509 KB

Activity of SU11248, a multitargeted inh

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors

✍ Aristidis Polyzos 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 106 KB

Cessation of vascular endothelial growth

Cessation of vascular endothelial growth factor–targeted therapy in patients with metastatic renal cell carcinoma : Feasibility and clinical outcome

✍ Sarmad Sadeghi; Laurence Albiges; Laura S. Wood; Shari L. Black; Timothy D. Gill 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

Everolimus in metastatic renal cell carc

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study

✍ E. Calvo; B. Escudier; R.J. Motzer; S. Oudard; T.E. Hutson; C. Porta; S. Bracard 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 262 KB